A recent phase II study (CheckRad-CD8) demonstrated the feasibility of single-cycle induction treatment with cisplatin–docetaxel and durvalumab combined with tremelimumab (anti-CTLA-4 mAb) and achieved a high biopsy-proven pathologic complete response (pCR) rate in patients with locally advanced HNSCC [95]. Here, CTLA4 is linked to head and neck squamous cell carcinoma.